The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 78.01 is strong.
Sunshine Guojian Pharmaceutical (Shanghai) Co has a Altman Z-Score of 78.01, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Altman Z-Score Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co Altman Z-Score vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Altman Z-Score of 78.01 as of Jul. 09, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 275% above median its historical median of 20.81. Over the past decade, Sunshine Guojian Pharmaceutical (Shanghai) Co's Altman Z-Score has ranged from 8.44 to 79.53. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #21 out of 924 companies in the Biotechnology industry, placing it in the top 2.3%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Altman Z-Score too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Altman Z-Score of 78.01 is 275% above median its 10-year median of 20.81. Over the past 10 years, this metric has ranged from a low of 8.44 to a high of 79.53. The Biotechnology industry median Altman Z-Score is 2.78. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 78.01 is 2711.2% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #21 out of 924 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #21 out of 924 companies for Altman Z-Score. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.78. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 78.01 is 2711.2% above this benchmark. Historically, Sunshine Guojian Pharmaceutical (Shanghai) Co's own Altman Z-Score has ranged from 8.44 to 79.53 over the past decade. While the company's 10-year median is 20.81 vs. the industry median of 2.78, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.78, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Altman Z-Score of 78.01 is 2711.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Altman Z-Score is 78.01, which is 275% above median its own 10-year median of 20.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.94, compared to a current price of ¥51.08 — trading 23.7% below its estimated fair value. The current Altman Z-Score is 78.01, which is 275% above median its 10-year median of 20.81 and 2711.2% above the Biotechnology industry median of 2.78. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Altman Z-Score is 78.01 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥51.08 is trading 23.7% below its estimated GF Value™ of ¥66.94.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688336:
Altman Z-Score: 78.01 (275% above median its 10-year median of 20.81)
GF Value™: ¥66.94 vs. price of ¥51.08 (23.7% below fair value)
Industry Position: 2711.2% above the Biotechnology median (#21 of 924)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
85GF Score
Get the complete analysis for SHSE:688336
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
